Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Manufacturing
etherna appoints Antonin de Fougerolles as new Chairperson
Tony has extensive experience in the development of novel therapeutic modalities, such as RNAis and modified mRNAs for vaccinations
Research & Development
etherna and Hasselt University collaborate to develop mRNA-based therapies for autoimmune disease
The collaboration will aim to develop treatments for multiple sclerosis, and is backed by Flanders Innovation & Entrepreneurship (VLAIO)
Manufacturing
etherna appoints Shelly West as Business Development Director, US
Shelly arrives from Cellpoint Biosciences and will be in charge of expanding etherna's US customer base
Ingredients
LNP formulation improves mRNA vaccine efficacy and tolerability
S-Ac7-DOG encapsulated mRNA demonstrated markedly higher transfection, lower reactogenicity, and higher accumulation in the vaccine draining lymph nodes
Research & Development
Almirall and etherna to develop mRNA-based therapies in medical dermatology
The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space
Manufacturing
eTheRNA Manufacturing announces LNP development service
The service uses the company’s proprietary lipid libraries and proprietary formulations to facilitate targeted delivery and tailored biodistribution solutions
Research & Development
eTheRNA announces mRNA research agreement with Merck
The ongoing pandemic has underlined the capability for mRNA vaccines as a therapeutic modality
Subscribe now